IL148777A0 - New formulation of mirtazapine - Google Patents

New formulation of mirtazapine

Info

Publication number
IL148777A0
IL148777A0 IL14877700A IL14877700A IL148777A0 IL 148777 A0 IL148777 A0 IL 148777A0 IL 14877700 A IL14877700 A IL 14877700A IL 14877700 A IL14877700 A IL 14877700A IL 148777 A0 IL148777 A0 IL 148777A0
Authority
IL
Israel
Prior art keywords
mirtazapine
new formulation
formulation
new
Prior art date
Application number
IL14877700A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148777(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL148777A0 publication Critical patent/IL148777A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL14877700A 1999-10-13 2000-10-09 New formulation of mirtazapine IL148777A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13
PCT/EP2000/009863 WO2001026621A2 (en) 1999-10-13 2000-10-09 Orally distintegrating composition comprising mirtazapine

Publications (1)

Publication Number Publication Date
IL148777A0 true IL148777A0 (en) 2002-09-12

Family

ID=8240737

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14877700A IL148777A0 (en) 1999-10-13 2000-10-09 New formulation of mirtazapine
IL148777A IL148777A (en) 1999-10-13 2002-03-20 Mirtazepine oral oral administration unit

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148777A IL148777A (en) 1999-10-13 2002-03-20 Mirtazepine oral oral administration unit

Country Status (28)

Country Link
EP (1) EP1223914B1 (ja)
JP (1) JP5561885B2 (ja)
KR (1) KR100708560B1 (ja)
CN (1) CN1173701C (ja)
AR (1) AR026010A1 (ja)
AT (1) ATE274899T1 (ja)
AU (1) AU780379B2 (ja)
BR (1) BR0014593A (ja)
CA (1) CA2386547C (ja)
CO (1) CO5251412A1 (ja)
CZ (1) CZ20021315A3 (ja)
DE (2) DE60013466T2 (ja)
ES (1) ES2194618T3 (ja)
HK (1) HK1046641B (ja)
HU (1) HUP0203148A3 (ja)
IL (2) IL148777A0 (ja)
MX (1) MXPA02003519A (ja)
NO (1) NO20021730L (ja)
NZ (1) NZ518165A (ja)
PE (1) PE20010699A1 (ja)
PL (1) PL200858B1 (ja)
PT (1) PT1223914E (ja)
RU (1) RU2261098C2 (ja)
SK (1) SK6452002A3 (ja)
TR (1) TR200200978T2 (ja)
TW (1) TWI256309B (ja)
WO (1) WO2001026621A2 (ja)
ZA (1) ZA200202293B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
CA2643802A1 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) * 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
CN109820830A (zh) * 2012-03-02 2019-05-31 罗德兹制药股份有限公司 抗破坏性立即释放型制剂类
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农（肇庆）生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
WO1991004757A1 (en) * 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
MXPA02003519A (es) 2002-08-20
HUP0203148A2 (hu) 2003-01-28
TWI256309B (en) 2006-06-11
EP1223914A2 (en) 2002-07-24
BR0014593A (pt) 2002-06-11
WO2001026621A2 (en) 2001-04-19
ES2194618T3 (es) 2005-04-01
NO20021730D0 (no) 2002-04-12
KR20020038946A (ko) 2002-05-24
NZ518165A (en) 2004-03-26
AR026010A1 (es) 2002-12-26
DE60013466T2 (de) 2005-01-20
HK1046641A1 (en) 2003-01-24
HUP0203148A3 (en) 2004-06-28
ZA200202293B (en) 2003-06-20
PL200858B1 (pl) 2009-02-27
WO2001026621A3 (en) 2001-10-11
CN1378452A (zh) 2002-11-06
KR100708560B1 (ko) 2007-04-19
EP1223914B1 (en) 2004-09-01
SK6452002A3 (en) 2002-09-10
PE20010699A1 (es) 2001-07-06
DE60013466D1 (de) 2004-10-07
RU2002112238A (ru) 2004-01-10
TR200200978T2 (tr) 2002-09-23
CA2386547C (en) 2010-06-08
CA2386547A1 (en) 2001-04-19
PL354584A1 (en) 2004-01-26
ATE274899T1 (de) 2004-09-15
CO5251412A1 (es) 2003-02-28
PT1223914E (pt) 2004-11-30
ES2194618T1 (es) 2003-12-01
JP5561885B2 (ja) 2014-07-30
CZ20021315A3 (cs) 2002-07-17
IL148777A (en) 2013-10-31
DE1223914T1 (de) 2003-09-18
AU780379B2 (en) 2005-03-17
AU1023201A (en) 2001-04-23
NO20021730L (no) 2002-05-30
CN1173701C (zh) 2004-11-03
JP2003511403A (ja) 2003-03-25
RU2261098C2 (ru) 2005-09-27
HK1046641B (zh) 2005-04-08

Similar Documents

Publication Publication Date Title
HUP0201489A3 (en) New formulation
TW450031U (en) Trousers of convenience
EP1156812A4 (en) MULTIPARTICULAR FORMULATION
EG24226A (en) Formulation
PL355101A1 (en) Use of h1
IL149107A0 (en) Formulation of substituted benzimidazoles
IL148777A0 (en) New formulation of mirtazapine
GB9905898D0 (en) Controlled-dose formulation
EG22530A (en) Preparation of substituted piperidin-4-ones
GB9902304D0 (en) Formulation
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
GB9924158D0 (en) Nebuliser
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9927614D0 (en) Sterliant formulation
HK1053059A1 (zh) 新用途
HK1054508A1 (zh) 新型製劑
GB9902236D0 (en) Formulation
GB9910667D0 (en) New use of citreamicins
CA87150S (en) Set of cutlery
CA88062S (en) Set of cutlery
GB9923538D0 (en) Formulation
GB9915584D0 (en) Formulation
GB9902089D0 (en) Formulation